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Abstract 
-glucan is a polysaccharide that is extracted from fungal cell walls. Wellmune WGP®, a 
preparation of -1,3/1,6-glucans, is a dietary supplement that has immunomodulating 
properties. Here we asked what affect WGP had on a mouse model of asthma. OVA-
induced asthma in mice is characterized by infiltration of eosinophils into the lung, 
production of Th2 cytokines and IgE production. WGP (400ug) or PBS was orally 
administered to OVA-challenged mice daily throughout the experiment. Administration 
of WGP significantly reduced the influx of eosinophils into the lungs of OVA-challenged 
mice compared to control mice. In addition, daily administration of WGP inhibited 
pulmonary production of Th2 cytokines (Il-4, IL-5, IL13), however serum IgE levels in 
the bronchoalveolar lavage fluid (BALF) were unaffected by WGP treatment. These data 
indicate that WGP could be useful as an oral supplement for some asthma patients, 
however, it would need to be combined with other therapies that target other aspects of 
the disease such as IgE levels. Additionally, WGP would need to be studied in 
combination with other therapies before administration to patients.  
Introduction 
Asthma is a chronic inflammatory airway disease that is caused by an allergic response in 
many cases. It affects 5-10% of the population and is associated with significant 
morbidity and mortality (1). It is characterized by airway inflammation, airway 
hyperresponsiveness (AHR) and mucus production (2). Lung inflammation is caused by 
infiltration of eosinophils and T cells secreting Th2-cytokines (IL-4, IL-5, IL-13) into the 
lung. IL-4, IL-5 and IL-13 are important for IgE production, eosinophil recruitment and 
survival, mucus secretion and AHR development (3). In addition to eosinophilic Th2-
associated asthma, other asthma phenotypes occur such as neutrophilic non-Th2 
associated asthma. Currently the main treatment for asthma is corticosteroid 
administration, however some asthma phenotypes are refractory to corticosteroid therapy 
(4). There is currently a significant level of research into the development of 
immunotherapies for asthma. These involve the targeting of IgE or cytokines such as IL-
4, IL-5, IL-13 or others. While many of these therapies are ineffective individually, 
researchers are currently examining the potential for combination therapies (5).  
 
-glucan, a fungal cell wall extract, is marketed as a dietary supplement that can promote 
immune balance (6). -glucans are found in the cell walls of fungi, plants and some 
bacteria.  3 or 6 linked glucans are recognized by the Dectin-1 
receptor. Dectin 1 is a type II transmembrane C-type lectin-like receptor, which 
recognizes both soluble and particulate -glucans (7-9). While Dectin-1 can bind both 
soluble and particulate -glucans, only particulate -glucans activate Dectin-1 signaling 
and responses (10). -glucan-induced signaling through Dectin-1 promotes Th1 and Th17 
responses (11).  
 
-glucan has been shown to exert beneficial therapeutic effects against various diseases. 
It has been shown to stimulate tumoricidal activity when co-administered with anti-tumor 
antibodies (12-17). However, divergent results regarding the effect of -glucan on 
respiratory health have been reported. It has been suggested that exposure to microbial 
products or mould can adversely affect the development of asthma (18), however recent 
data suggest that -glucans and other microbial signals may play a protective role for the 
development of asthma (19). -glucan administration has been shown to prevent/improve 
symptoms of allergic rhinitis and upper respiratory tract infections (20, 21). However, 
there is minimal data on the effect of -glucan on asthma severity (22). In this study, we 
therefore examined the effect of oral administration of particulate -glucan (WGP) in a 
mouse model of ovalbumin (OVA)-induced asthma. Here we demonstrate that oral 
administration of WGP reduces eosinophil influx and the production of Th2 cytokines 
(IL-4, Il-5, IL-13) in the lungs of OVA-challenged mice. 
 
Material and Methods 
Animals 
C57BL/6 mice were maintained under specific pathogen-free conditions at the NCI–
Frederick, MD. Animal care was provided in accordance with the procedures in, “A 
Guide for the Care and Use of Laboratory Animals”. Ethical approval for the animal 
experiments detailed in this manuscript was received from the Institutional Animal Care 
and Use Committee at the NCI-Frederick. 
 
Oral administration of PBS or WGP 
Mice were treated daily with 25-100μl PBS containing 400μg Wellmune WGP from 
Biothera (Eagen, MN) or PBS alone by oral gavage or alternatively by feeding by pipet 
as needed. Treatment was started seven days prior to beginning OVA sensitization, and 
was continued for the duration of the study. 
 
Sensitization and airway challenge 
Allergic airway hypersensitivity to ovalbumin (OVA) was induced using grade V chicken 
egg OVA (Sigma, St. Louis, MO). Sensitization was initiated by an intraperitoneal (i.p.) 
injection of 100μg OVA in 200μl of 11-13mg/ml aluminum hydroxide colloidal 
suspension (Alum), followed by a second i.p. injection two weeks later. Ten days after 
the last sensitization, airway hypersensitivity was induced by 20-minute nebulization 
sessions challenging with 1% (w/v) OVA in PBS for four consecutive days. Mice were 
sacrificed, and tissues harvested 24h after the last nebulization. A schematic of the 
treatment schedule is shown in Fig. 1. 
 
Bronchoalveolar lavage fluid collection 
Prior to BALF collection, mice were given a ketamine/xylazine mixture to induce deep 
anesthesia and analgesia. Once sedated, as determined by toe-pinch, the thoracic cavity 
was opened to reveal the lungs and trachea. Using a cannula and leur lock syringe, the 
lungs were expanded using 1mL of PBS and recollected as BALF, for a total of 2-3 
washes. The mice were euthanized by heart perfusion using 5-10mL PBS, and the lungs 
and other tissues were collected. 
 
BALF cytospin and differential cell count analysis 
Cells from the BAL were collected, and the BALF was saved for cytokine analysis. Red 
blood cell lysis was performed if necessary, cells were washed in PBS, and then counted 
using a hemacytometer. 100μL containing approximately 5x104 cells were loaded onto a 
cytospin column and centrifuged onto a microscope slide. Following Diffquick cell 
staining, differential cell counts were blindly assessed for each sample, counting at least 
500 cells per slide. 
 
BALF Assays 
BALF was clarified by centrifugation, aliquoted and stored at -80°C for later analysis. 
Cytokine levels were measured in BALF using ELISA kits from eBioscience (San Diego, 
CA) and R&D Systems (Minneapolis, MN). Myeloperoxidase (MPO) activity in BALF 
samples was measured using the Myeloperoxidase activity fluorometric assay kit from 
BioVision (Mountain View, CA). Eosinophil peroxidase (EPO) in BALF samples was 
measured using the Eosinophil peroxidase ELISA kit from antibodies-online.com 
(Atlanta, GA). Soluble collagen levels in BALF were measured using the previously 
described protocol in Current Protocols in Immunology. Briefly 200µl of 0.1% Direct 
Red 80 in picric acid (Sigma Aldrich, St. Louis, MO) was added to 50µl of lavage fluid 
and incubated for 60min at 37°C. The samples were centrifuged and the pellet was 
washed with 100% ethanol.  The pellet was resuspended in 200µl 0.5M NaOH, incubated 
for 30min at 37°C and the absorbance was read at 540nm.  
 
Lung and spleen cell isolation and flow cytometry 
Lung cells were isolated by collagenase and DNase digestion (Sigma Aldrich). 
Splenocytes were mashed through 100µm nylon cell strainers and erythrocytes were 
lysed in ACK buffer. Lung cells were washed with HBSS and splenocytes were washed 
with PBS. Lung cells and splenocytes were pre-incubated with 2.4G2 to block Fc 
receptor binding, followed by incubation with various cell surface Abs: CD3 (17-A2), 
NK1.1 (PK136), B220 (RA3-6B2), F4/80 (BM8), MHCII (M5/114.15.2), (eBioscience, 
San Diego, CA), Siglec F (E50-2440), CD11c (N418), CD11b (M1/70), Gr-1 (RB6-8C5) 
and Ly6G (1A8) (BD Biosciences, San Jose, CA). Cells were fixed with BD Cytofix and 
analysed on BD LSRII. 
 
Blood cell measurement 
Blood samples were taken prior to the start of the experiment, and again on the day of 
harvest. Cell composition was measured using the Hemavet 950 automated blood cell 
counter, (Drew Scientific, Waterbury, CT), according to the manufacturer’s protocol. 
 
RNA isolation and analysis 
A portion of the lung was excised and placed in Trizol for RNA isolation. The lung tissue 
in Trizol was homogenized using a mini-beadbeater. RNA was extracted using the Trizol 
protocol and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was 
synthesized using Taqman Reverse Transcription Reagents for RT-PCR (Applied 
Biosystems). Quantitative RT-PCR was performed using ABI Taqman Primer and Probe 
sets and normalization was performed against Hprt1. 
 
Measurement of IgE 
Total IgE levels in serum were measured using the IgE ELISA from BD Biosciences (San 
Jose, CA). OVA specific IgE was measured using the Legend Max Mouse OVA Specific 
IgE ELISA kit from Biolegend (San Diego, CA). 
 
Lung Histology 
The lungs were placed in 10% formalin, embedded in paraffin wax blocks and 4μm 
sections cut and stained for either haematoxylin and eosin (H&E) or periodic acid Schiff 
(PAS) to determine airway inflammation and goblet cell metaplasia respectively. All 
histological sections were assessed blind by a pathologist and the total number of 
bronchiole and perivascular aggregates of inflammatory cells were counted in each lung. 
Mucous cell metaplasia within the bronchioles was compared to normal control tissue 
and graded as 0 = no difference, 1 = scattered mucous cells, 2 = aggregates of mucous 
cells, 3 = monolayer layer of mucous cells and 4 = multilayered mucous cells. 
 
Statistical analysis 
Data are expressed as means +/- s.e.m. Statistical significance was determined using 
Student’s t-test or 1-way ANOVA followed by Bonferroni’s post-test. Statistical 
significance was set at *p<0.05, **p<0.01, ***p<0.001. 
 Results 
WGP reduces total BALF cell numbers and eosinophil accumulation. To examine the 
effect of orally administered WGP on allergic airway inflammation, we sensitized and 
challenged WT mice with OVA. Oral administration of WGP affected the composition of 
cells recovered from the BALF. The total number of cells, total number of eosinophils 
and the percentage of macrophages were significantly reduced while the percentage of 
neutrophils was increased in the WGP-treated mice (Fig. 2A-B). MPO activity and EPO 
levels correspond to the number of neutrophils and eosinophils, respectively in a sample. 
While the percentage of neutrophils was increased in WGP-treated mice, MPO activity in 
the BALF was similar between PBS and WGP-treated mice (Fig. 2C). This is likely due 
to the similar total number of neutrophils in the BALF from PBS and WGP-treated mice. 
EPO levels were reduced in WGP-treated mice (Fig. 2D), which is consistent with the 
reduced eosinophil numbers in the BALF from these mice. These data indicate that oral 
administration of WGP significantly inhibits the recruitment of inflammatory cells, in 
particular eosinophils and to a lesser extent macrophages, to the lungs in this model of 
allergic inflammation. 
 
WGP modulates lung cellular composition. As we observed differences in BALF 
cellular composition, we examined the effect of WGP on lung cellular composition. 
Similar to our findings in BALF, eosinophils and macrophages (percentage and total cell 
number) were reduced, while the percentage of neutrophils was increased in the lungs of 
WGP-treated mice compared to PBS-treated mice (Fig. 3A-B). Taken together these data 
indicate that WGP significantly inhibits the recruitment of eosinophils and macrophages 
to the lungs of these mice while it promotes a modest increase in neutrophil recruitment. 
 
WGP modulates systemic cellular composition. As WGP was administered orally to 
the mice and modulated cellular composition in the lung, we next wanted to determine 
whether it had any systemic effect on cellular composition in the blood or other organs. 
Similar to the BALF and lung findings, WGP administration did not significantly affect 
the total number of neutrophils (Fig. 4A & C), however it modestly increased the 
percentage of neutrophils in both the spleen and blood (Fig. 4B &D). The WBC count 
was higher in WGP-treated mice, while a small decrease in the percentage of 
lymphocytes, corresponding to the increase in the percentage of neutrophils, was 
observed in these mice (Fig. 4C-D). Interestingly, similar total cell numbers/percentages 
of eosinophils and monocytes/macrophages were observed in the spleen and the blood. 
These data indicate that the increase in BALF/lung neutrophils is due to a systemic 
increase in neutrophils while the BALF/lung decrease in eosinophils and macrophages is 
localized suggesting reduced recruitment.  
 
WGP does not effect OVA-induced histopathological changes in the lung. To 
determine the effect of WGP on OVA-induced histopathological changes in the lung, 
lung sections were stained with H&E and scored. Variable changes were seen in different 
areas of the lung with a mixed inflammatory cell infiltrate predominantly observed in 
peribronchial and perivascular areas in OVA-challenged mice; however, WGP had no 
effect on these changes (Fig. 5A-B, C-D & G). Similar features were seen in bronchioles 
of both PBS and WGP-treated mice with folded epithelium and narrowing of lumens and 
no differences in goblet cell metaplasia or mucous production (Fig. 5C, F & H).  Lung 
fibrosis/airway remodeling is characterized by enhanced collagen deposition (23). 
Soluble collagen levels in the lung were similar between PBS and WGP-treated mice 
(Fig. 5I), demonstrating that some aspects of the airway hyperesponsiveness model are 
unaffected by WGP treatment.  
 
WGP reduces Th2 cytokine levels in the lung. Th2 cells secreting IL-4, IL-5 and IL-13 
are important for eosinophil recruitment and survival and for IgE production (24). To 
further investigate the effect of WGP on allergic inflammation, cytokine levels (Th1, Th2 
and Th17) in the lungs of PBS and OVA-challenged mice were measured. Consistent 
with previously published data from this model, OVA challenged mice displayed 
increased levels of these cytokines in the lungs compared to PBS challenged mice (data 
not shown). Interestingly, the levels of Il4 and Il5 mRNA, which are important for 
eosinophil recruitment, along with Il13, were reduced in the lungs of WGP-treated OVA-
challenged mice (Fig. 6A). Th1 (Ifng) and Th17 (Il17) cytokine mRNA levels were 
similar between PBS and WGP-treated OVA-challenged mice. In addition Foxp3 mRNA 
levels, found in Tregs, were also measured and were similar between PBS and WGP-
treated mice (Fig. 6A). Consistent with the mRNA data, IL-4, IL-5 and IL-13 protein 
levels were significantly reduced in WGP-treated mice while IFN- and IL-17 levels 
were mostly not detected (Fig. 6B and data not shown). As IgE production is an 
important aspect of the OVA-challenge asthma model, we next examined IgE production 
in the serum of these mice. Total IgE levels and OVA-specific IgE levels (Fig. 6C) were 
similar between PBS and WGP-treated mice. Together, these data demonstrate reduced 
Th2 cytokine production in WGP-treated mice compared to PBS-treated mice while Th1 
and Th17 cytokine levels are similar between the two groups.  
 
 
Discussion 
Several natural products are advertised as immunotherapeutics and many claims are made 
about their effects on a wide range of diseases including asthma. Here we tested the effect 
of Wellmune WGP -1,3/1,6-glucan during a mouse model of OVA-induced asthma. We 
demonstrated that daily oral administration of WGP reduces eosinophil influx into the 
lungs and the production of Th2 cytokines (IL-4, IL-5, IL-13) compared to control mice. 
Serum IgE levels and OVA-specific IgE levels were unaffected by administration of 
WGP. Together these data indicate that WGP administration would not be sufficient as a 
single treatment for asthma however it may prove useful as a combination therapy.  
 
Asthma is a heterogeneous disease and patients present with various distinct clinical 
phenotypes. Different mouse models are being developed to model the different 
phenotypes found in asthma patients (3, 25, 26). The OVA-induced airway 
hypersensitivity model of asthma used here results in eosinophilic inflammation in the 
lung, pulmonary production of Th2 cytokines (IL-4, IL-5 and IL-13) and serum IgE 
production (3, 26). The role of Th2 cells in patients with asthma is well established and T 
cell activation has been related to asthma severity in some studies (27, 28). IL-4, IL-5 and 
IL-13 have been shown to have roles in IgE production, eosinophil survival, AHR 
development and tissue remodeling (29). Here we observed a significant reduction in 
production of Th2 cytokines and eosinophil influx, however IgE production and soluble 
collagen levels were unaffected by the administration of WGP. Other factors in addition 
to Th2 cells/cytokines are involved in the pathogenesis of asthma (3) however it appears 
that WGP is specific in targeting the production of IL-4, IL-5, IL-13 and resulting 
eosinophilia in this model while it has no effect against other aspects of the disease.   
 
-glucan has immunomodulating properties and it has been shown to exert beneficial 
therapeutic effects against various diseases including allergic diseases. One study 
demonstrated that administration of WGP to ragweed allergy sufferers reduced allergy 
symptoms however similar to our findings it had no effect on serum IgE levels (30). 
Another study showed that -glucan administration to subjects with seasonal allergic 
rhinitis resulted in reduced IL-4 and IL-5 levels (31). Our data demonstrating reduced IL-
4 and IL-5 levels in WGP-treated mice in an OVA-induced asthma model is in agreement 
with these findings. In addition a study demonstrated a reduction in asthmatic symptoms 
following -glucan administration and increased IL-10 levels (22). 
 
Our findings suggest that WGP could be used to target some aspects of asthma (Th2 
cytokines and eosinophilia). While WGP alone would not be sufficient to treat asthma, it 
could be used in combination with other therapies that target different aspects of the 
disease such as IgE levels. As WGP is an oral supplement, it could be considerably more 
cost effective and may have fewer side effects than immunotherapies. In addition, as IL-
4, IL-5 and IL-13 are all reduced in response to WGP, the broader effects of WGP could 
be more beneficial than immunotherapies that target one specific cytokine such as IL-4 or 
IL-5. Further studies would need to be conducted to determine the effect of WGP in 
combination with other therapies for specific subsets of asthma patients. 
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Figure Legends 
 
Figure 1. Schematic for induction of airway inflammation and treatment with WGP. PBS 
or 400μg WGP in PBS was orally administered to mice daily via oral gavage or pipette 
feeding. Oral administration of PBS or WGP began 7 days prior to sensitization with 
ovalbumin (OVA)/Alum and continued daily for the duration of the experiment. Mice 
were sensitized via i.p. injection of 100μg OVA in 1.8-2.6mg Alum on Days 0 and 14. 
Mice were challenged with OVA (1% w/v in PBS) for 20min using a nebulizer on Days 
24, 25, 26 and 27. Mice were euthanized 24h following the last challenge.  
 
Figure 2. Effect of oral administration of WGP on BALF cells in OVA-challenged mice. 
Cell numbers (A) and percentages (B) in BALFs from OVA-challenged mice fed with 
PBS or WGP. Graphs display mean +/- s.e.m. from 4 independent experiments, 
n=19/group. (C) MPO Activity in BALF. Graph displays mean +/- s.e.m. from 5 
independent experiments (n=21-22/group). (D) EPO levels in BALF. Graph displays 
mean +/- s.e.m. from 3 independent experiments (n=15/group). 
 
Figure 3. Effect of oral administration of WGP on lung cellular composition in OVA-
challenged mice. Cell numbers (A) and percentages (B) in lungs from OVA-challenged 
mice fed with PBS or WGP. Graphs display mean +/- s.e.m. from 3 independent 
experiments, n=13-14/group.  
 
Figure 4. Effect of oral administration of WGP on spleen and blood cellular composition 
in OVA-challenged mice. Cell numbers (A) and percentages (B) in spleens from OVA-
challenged mice fed with PBS or WGP. Graph displays mean +/- s.e.m. from 3-4 
independent experiments, n=14-19/group. Cell numbers (C) and percentages (D) in blood 
from OVA-challenged mice fed with PBS or WGP. Graph displays mean +/- s.e.m. from 
2 independent experiments, n=8-10/group. 
 
Figure 5. Effect of oral administration of WGP on lung histology and soluble collagen. 
(A-F) Representative sections from both treatment groups demonstrate the varied 
morphological changes seen within the lung. H&E sections from a representative mouse 
treated with PBS (A - B) demonstrate more prominent epithelial infolding and lumen 
reduction related to mucous cell metaplasia. The surrounding tissue shows peribronchiole 
and perivascular inflammatory infiltrates comprising lymphocytes with scattered 
eosinophils.  Similar features were seen in a representative mouse treated with WGP (D - 
E) although in this section the changes within the bronchiole are subtle and the 
lymphcytic infiltrate denser. PAS stains from different areas reveal mucous cell 
metaplasia in each group (C and F). (G-H) Graphs display mean +/- s.e.m. Inflammatory 
Focus Score (G) and Mucus Cell Score (H). Graphs are the cumulative result of 2 
independent experiments (n=10). (I) Graph displays mean +/- s.e.m. of soluble collagen 
levels in BALF. Graph is the cumulative result of 5 independent experiments (n=22-23). 
 
Figure 6. Cytokine levels and IgE levels in OVA-challenged mice. (A) RNA was 
extracted from lung tissue from OVA-challenged mice fed with PBS or WGP. Il4, Il5, 
Il13, Ifng, Il17 and Foxp3 mRNA levels were analyzed by Real Time qPCR. Graphs 
display mean +/- s.e.m. from 3 independent experiments, n=14-15/group. (B) Cytokine 
levels were measured in BALF by ELISA. Graphs display mean +/- s.e.m. from 3 
independent experiments, n=12-15/group. (C) Total IgE and OVA-specific IgE levels 
were measured in the serum by ELISA. Graph displays mean +/- s.e.m. from 5 
independent experiments, n=23-25/group.  
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